PREDNISONE THERAPY SAFETY FOR TREATMENT OF PATIENTS WITH MIX OF TUBERCULOSIS AND HIV-INFECTION
Medical Immunology
View Archive Info| Field | Value | |
| Title |
PREDNISONE THERAPY SAFETY FOR TREATMENT OF PATIENTS WITH MIX OF TUBERCULOSIS AND HIV-INFECTION
БЕЗОПАСНОСТЬ ТЕРАПИИ ПРЕДНИЗОЛОНОМ В ЛЕЧЕНИИ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ И ВИЧ-ИНФЕКЦИЕЙ |
|
| Creator |
G. Maksimov V.; City Tuberculosis Dispensary, St. Petersburg
S. Mukomolov L.; Saint Petersburg Pasteur Institute, St. Petersburg A. Ivanov K.; Tuberculosis Research Institute, St. Petersburg Г. Максимов В.; ГБУЗ Городской противотуберкулезный диспансер, Санкт-Петербург С. Мукомолов Л.; ФБУН НИИ эпидемиологии и микробиологии имени Пастера, Санкт-Петербург А. Иванов К.; ФГБУ Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии МЗ РФ |
|
| Subject |
HIV infection; tuberculosis; prednisone
ВИЧ-инфекция; туберкулез; преднизолон |
|
| Description |
Abstract. The study of prednisone safety for treatment of TB mixed with HIV-infection has been conducted. Two groups of patients were compared. The first group was consisted of 88 patients who were treated by prednisone and standard tuberculosis therapy, the second group of patients presented by 45 patients received only tuberculosis medicines. It was demonstrated that in case of prednisone using (1st group) the number of CD4 limphocytes increased, intoxication symptoms disappeared fast and recovery process accelerated. Increasing of cases with unfavorable course of TB and HIV-infection in patients of first group was not registered in compare with the second group. Thus, using of prednisone therapy to treat TB mixed with HIV-infection was safe, not lead to unfavorable course of TB or HIV-infection. Such kind of treatment especially important for patients with exudative reactions.
Резюме. Проведено изучение безопасности применения преднизолона у больных ВИЧ-инфекцией и туберкулезом. Сравнивали две группы. Первая группа, 88 больных, получали преднизолон и стандартную противотуберкулезную терапию, вторая группа, 45 больных — только противотуберкулезные препараты. Показано, что на фоне приема преднизолона увеличивалось число CD4 лимфоцитов, быстрее исчезали симптомы интоксикации, и ускорялось выздоровление пациентов с экссудативными формами туберкулеза в первой группе. Не было отмечено случаев неблагоприятного течения туберкулеза и ВИЧ-инфекции по сравнению со второй группой. Таким образом, использование преднизолона для лечения туберкулеза у ВИЧ-инфицированных пациентов безопасно, не ведет к неблагоприятному течению ВИЧ-инфекции и туберкулеза. Такое лечение особенно показано больным с экссудативными реакциями. |
|
| Publisher |
Publishing house of Saint Petersburg Pasteur Institute
|
|
| Contributor |
—
— |
|
| Date |
2014-07-08
|
|
| Type |
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion — — |
|
| Format |
application/pdf
|
|
| Identifier |
http://iimmun.ru/index.php/iimm/article/view/143
10.15789/2220-7619-2013-4-341–346 |
|
| Source |
Russian Journal of Infection and Immunity; Том 3, № 4 (2013); 341–346
Инфекция и иммунитет; Том 3, № 4 (2013); 341–346 2313-7398 2220-7619 10.15789/2220-7619-2013-4 |
|
| Language |
rus
|
|
| Relation |
http://iimmun.ru/index.php/iimm/article/view/143/142
|
|
| Rights |
Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
|
|